Trial of mild immunosuppression by methisoprinol in acute onset diabetes mellitus: effects on rate and duration of remission.
There is a lot of data that suggests the immune system plays a role in the pathogenesis of Type 1 DM. Methisoprinol, an immunomodulatory drug, has been reported as being efficient in preventing DM induced by a low dose of streptozotocin in mice. The efficiency of this drug in Type 1 DM was assessed by the rate and duration of remission obtained in recent acute onset DM by strict blood glucose control. We used 2 different therapeutic procedures successively: one was short in an anti-viral aim (50 mg/kg body wt. daily during 10 days) and the other longer given as immunomodulatory treatment (50 mg/kg body wt. daily during 2 weeks and 30 mg/kg body wt. daily during 4 weeks more) with reinduction (30 mg/kg body wt. daily during 4 weeks) every 5 months. No side effect was observed during the treatment. In both studies there was no improvement in the rate and duration of remission when compared to controls; residual beta-cell function was not increased after treatment by methisoprinol. Mild immunotherapy did not appear helpful in Type 1 DM.
D000293:Adolescent; D000328:Adult; D002096:C-Peptide / Q000097:blood; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000627:therapeutic use*; D008297:Male; D012074:Remission Induction
D002096:C-Peptide; D007288:Inosine; D007542:Inosine Pranobex